| 1. |
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
- Niemi, MEK, et al.
(författare)
-
- 2021
-
swepub:Mat__t
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
- Juhlin, Christopher, et al.
(författare)
-
Reappraisal of deep seismic reflection Profile VIII across the Pripyat Trough
- 1996
-
Ingår i: Tectonophysics. - : Elsevier. - 0040-1951 .- 1879-3266. ; 268:1-4, s. 99-108
-
Tidskriftsartikel (refereegranskat)abstract
- Two, deep (24 s), multi-channel seismic reflection profiles, each >200 km in length, were shot across the Pripyat Trough, a Late Devonian rift basin in Belarus, in the 1980s by the Polessian Geophysical Expedition of the former Soviet Union. Additional post-stack processing and migration on one of these, Profile VIII, has been applied at Uppsala University and allows a re-evaluation of the crustal structure of the Pripyat Trough with particular focus on the deeper parts. Previous interpretations showed numerous steeply dipping faults extending from the surface to depths of 30–40 km and sometimes penetrating into the mantle, which was defined to be located at the top of a reflective zone beginning at about 10 s TWT. This reflective zone, recorded to depths of 16 s TWT, was interpreted as a mixture of crustal and mantle rocks. Based on the original stacked section and the further processing the reflective zone is reinterpreted to be reflective lower crust, not upper mantle, and the Moho is identified to be at 45–50 km (about 15 s TWT). The major basin bounding faults appear to be listric at depth and sole into the top of the reflective lower crust rather than be truncated by it. The newly interpreted crustal structure is consistent with a model of continental rifting involving brittle failure in a thick upper crustal layer and ductile shear in the lowermost crust with some degree of detachment between crust and mantle within the lower crustal ductile layer.
|
|
| 11. |
|
|
| 12. |
|
|
| 13. |
|
|
| 14. |
- Ruilope, LM, et al.
(författare)
-
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
- 2019
-
Ingår i: American journal of nephrology. - : S. Karger AG. - 1421-9670 .- 0250-8095. ; 50:5, s. 345-356
-
Tidskriftsartikel (refereegranskat)abstract
- <b><i>Background:</i></b> Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. <b><i>Patients and</i></b> <b><i>Methods:</i></b> The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate ≥25 mL/min/1.73 m<sup>2</sup> and albuminuria (urinary albumin-to-creatinine ratio ≥30 to ≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. <b><i>Conclusions:</i></b> FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049.
|
|
| 15. |
|
|
